Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2024

BIOQ

BIOQUAL, Inc. (OTC Pink:BIOQ) www.bioqual.com:

Three Months Ended

August 31,

2023

2022

Revenue

$

15,578,922

$

15,810,574

Income Before Income Tax

$

1,241,183

$

1,955,660

Net Income

$

899,483

$

1,383,560

Basic Earnings per Share
of Common Stock

$

1.01

$

1.55

Diluted Earnings per Share
of Common Stock

$

1.01

$

1.55

Weighted Average
Number of Shares Outstanding
For Basic Earnings Per Share

894,416

894,416

Weighted Average
Number of Shares Outstanding
For Diluted Earnings Per Share

894,406

894,405

For more detail related to the fiscal year 2024 unaudited first quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.